{"protocolSection":{"identificationModule":{"nctId":"NCT00623779","orgStudyIdInfo":{"id":"D1250C00051"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)","officialTitle":"A Controlled, Randomized, Parallel , Multi-centre Feasibility Study of the Oral Direct Thrombin Inhibitor, AZD0837, Given as ER Formulation, in the Prevention of Stroke and Systolic Embolic Events in Patients With Atrial Fibrillation, Who Are Appropriate for But Unable/Unwilling to Take VKA Therapy"},"statusModule":{"statusVerifiedDate":"2012-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-10"},"primaryCompletionDateStruct":{"date":"2008-10","type":"ACTUAL"},"completionDateStruct":{"date":"2008-10","type":"ACTUAL"},"studyFirstSubmitDate":"2008-02-15","studyFirstSubmitQcDate":"2008-02-15","studyFirstPostDateStruct":{"date":"2008-02-26","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-06-30","resultsFirstSubmitQcDate":"2011-06-30","resultsFirstPostDateStruct":{"date":"2011-07-28","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-03-20","lastUpdatePostDateStruct":{"date":"2012-03-23","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety and tolerability of AZD0837 in patients with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for up to 3 months."},"conditionsModule":{"conditions":["Persistent or Permanent Non-valvular Atrial Fibrillation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":128,"type":"ACTUAL"}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"AZD0837","description":"ER formulation"},{"type":"DRUG","name":"Aspirin","description":"Oral form"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Premature Discontinuation of Study or Study Drug Due to Any Reason","description":"The premature discontinuation of study or study drug due to any reason","timeFrame":"28 week (randomisation visit to last follow up visit in study) according to protocols"},{"measure":"Premature Discontinuation of Study Drug Due to Any Reason","description":"The premature discontinuation of study drug due to any reason","timeFrame":"24 weeks (randomisation visit to last treatment visit)"},{"measure":"Premature Discontinuation of Study Due to Any Reason","description":"\\|The premature discontinuation of study due to any reason","timeFrame":"28 weeks (randomisation visit to last follow up visit)"},{"measure":"Compliance With Study Drug","description":"\\[(number of doses dispensed-number of doses returned)/number of days between visits\\]\\*100","timeFrame":"24 weeks (randomisation visit to last treatment visit) according to protocol"},{"measure":"Compliance With Study Visits/Assessments","description":"(number of visits attended acroos the time of study divided by the number of expected visits according to the time of entry into study)\\*100","timeFrame":"28 weeks (randomisation visit to last follow up visit) according to protocol"}],"secondaryOutcomes":[{"measure":"Bleeding Events","description":"Number of patients with a bleeding event while on study drug. Patients with multiple bleeding events are counted once","timeFrame":"24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was <24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)"},{"measure":"Change in Creatinine Level","description":"Individual change in Creatinine level (umil/L) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)","timeFrame":"4 weeks according to protocol (randomisation visit to week 4 visit)"},{"measure":"Alanine Aminotransferase (ALAT)","description":"Number of patients while on study drug with Alanine aminotransferase (ALAT)\\>=3 times upper limit of normal.","timeFrame":"24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was <24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)"},{"measure":"Bilirubin","description":"Number of patients while on study drug with Bilirubin\\>=2 times upper limit of normal.","timeFrame":"24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was <24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)"},{"measure":"Plasma Concentration of AZD0837 (Prodrug)","description":"Assessment of plasma concentration of AZD0837 (prodrug) made on the week 4 visit","timeFrame":"4 weeks after baseline according to protocol"},{"measure":"Plasma Concentration of AR-H067637XX (Active Metabolite)","description":"Assessment of plasma concentration of AR-H067637XX (active metabolite) made on the week 4 visit","timeFrame":"4 weeks after baseline according to protocol"},{"measure":"Change in D-Dimer Level","description":"Individual change in D-Dimer level (ng/ml) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)","timeFrame":"4 weeks according to protocol.(baseline to week 4 visit)"},{"measure":"Activated Partial Thromboplastin Time (APTT)","description":"Individual change in Activated partial thromboplastin time (APTT) (sec) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)","timeFrame":"4 weeks according to protocol.(baseline to week 4 visit)"},{"measure":"Ecarin Clotting Time (ECT)","description":"Individual change in Ecarin clotting time (ECT) (sec) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)","timeFrame":"4 weeks according to protocol.(baseline to week 4 visit)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Either one of the following risk factors is sufficient for inclusion (high risk patient)\n* Previous cerebral ischaemic attack (stroke or transient ischaemic attack (TIA), \\>30 days prior to randomization)\n* Previous systemic embolism or at least one of the following risk factors are needed for inclusion: Age â‰¥75 years\n* Symptomatic congestive heart failure\n* Impaired left ventricular systolic function\n* Diabetes mellitus; Hypertension requiring anti-hypertensive treatment\n* In addition to AF the patient must be appropriate for but unable or unwilling to take VKA therapy\n\nExclusion Criteria:\n\n* Presence of a clinically significant valvular heart disease;; Stroke or TIA and/or systemic embolism within the previous 30 days prior to randomization\n* Conditions associated with increased risk of major bleeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Gregory Y Lip, MD","affiliation":"Birmingham City Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Research Site","city":"Aalborg","country":"Denmark","geoPoint":{"lat":57.048,"lon":9.9187}},{"facility":"Research Site","city":"Arhus N","country":"Denmark","geoPoint":{"lat":56.15674,"lon":10.21076}},{"facility":"Research Site","city":"Copenhagen","country":"Denmark","geoPoint":{"lat":55.67594,"lon":12.56553}},{"facility":"Research Site","city":"Esbjerg","country":"Denmark","geoPoint":{"lat":55.47028,"lon":8.45187}},{"facility":"Research Site","city":"Frederikssund","country":"Denmark","geoPoint":{"lat":55.83956,"lon":12.06896}},{"facility":"Research Site","city":"Horsens","country":"Denmark","geoPoint":{"lat":55.86066,"lon":9.85034}},{"facility":"Research Site","city":"Kobenhavn","country":"Denmark","geoPoint":{"lat":55.67594,"lon":12.56553}},{"facility":"Research Site","city":"Silkeborg","country":"Denmark","geoPoint":{"lat":56.1697,"lon":9.54508}},{"facility":"Research Site","city":"Svendborg","country":"Denmark","geoPoint":{"lat":55.05982,"lon":10.60677}},{"facility":"Research Site","city":"Elverum","country":"Norway","geoPoint":{"lat":60.88191,"lon":11.56231}},{"facility":"Research Site","city":"Gjettum","country":"Norway"},{"facility":"Research Site","city":"Kongsberg","country":"Norway","geoPoint":{"lat":59.66858,"lon":9.65017}},{"facility":"Research Site","city":"Oslo","country":"Norway","geoPoint":{"lat":59.91273,"lon":10.74609}},{"facility":"Research Site","city":"Stovner","country":"Norway","geoPoint":{"lat":59.95613,"lon":10.93174}},{"facility":"Research Site","city":"Straume","country":"Norway"},{"facility":"Research Site","city":"Bytom","country":"Poland","geoPoint":{"lat":50.34802,"lon":18.93282}},{"facility":"Research Site","city":"Czestochowa","country":"Poland","geoPoint":{"lat":50.79646,"lon":19.12409}},{"facility":"Research Site","city":"Krakow","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Research Site","city":"Lodz","country":"Poland","geoPoint":{"lat":51.75,"lon":19.46667}},{"facility":"Research Site","city":"Lublin","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"Research Site","city":"Ostrow Mazowiecka","country":"Poland","geoPoint":{"lat":52.80245,"lon":21.89507}},{"facility":"Research Site","city":"Otwock","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Research Site","city":"Plock","country":"Poland","geoPoint":{"lat":52.54682,"lon":19.70638}},{"facility":"Research Site","city":"Ruda Slaska","country":"Poland","geoPoint":{"lat":50.2584,"lon":18.85632}},{"facility":"Research Site","city":"Sopot","country":"Poland","geoPoint":{"lat":54.4418,"lon":18.56003}},{"facility":"Research Site","city":"Torun","country":"Poland","geoPoint":{"lat":53.01375,"lon":18.59814}},{"facility":"Research Site","city":"Warszawa","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Research Site","city":"Wroclaw","country":"Poland","geoPoint":{"lat":51.1,"lon":17.03333}},{"facility":"Research Site","city":"Moscow","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Research Site","city":"St. Petersburg","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Boras","country":"Sweden","geoPoint":{"lat":57.72101,"lon":12.9401}},{"facility":"Research Site","city":"Goteborg","country":"Sweden","geoPoint":{"lat":57.70716,"lon":11.96679}},{"facility":"Research Site","city":"Lund","country":"Sweden","geoPoint":{"lat":55.70584,"lon":13.19321}},{"facility":"Research Site","city":"Malmo","country":"Sweden","geoPoint":{"lat":55.60587,"lon":13.00073}},{"facility":"Research Site","city":"Molndal","country":"Sweden","geoPoint":{"lat":57.6554,"lon":12.01378}},{"facility":"Research Site","city":"Stockholm","country":"Sweden","geoPoint":{"lat":59.33258,"lon":18.0649}},{"facility":"Research Site","city":"Birmingham","country":"United Kingdom","geoPoint":{"lat":52.48142,"lon":-1.89983}},{"facility":"Research Site","city":"Eastbourne","country":"United Kingdom","geoPoint":{"lat":50.76871,"lon":0.28453}},{"facility":"Research Site","city":"Newcastle Upon Tyne","country":"United Kingdom","geoPoint":{"lat":54.97328,"lon":-1.61396}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"For participants treated with Vitamin K Antagonists (VKA) at the time of enrollment, VKA treatment was to be adjusted (and stopped before randomisation) to ensure that INR was below 2.0 at randomisation. If this was not achieved the participant was discontinued from the study.","recruitmentDetails":"The study population included male and female participants \\>18 years of age with chronic non-valvular Atrial Fibrillation. The participants were recruited during the time period from 22 October 2007 to 21 October 2008 at medical clinics in Europe.","groups":[{"id":"FG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"FG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"FG002","title":"Standard Therapy","description":"Standard Therapy"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"42"},{"groupId":"FG002","numSubjects":"45"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"39"},{"groupId":"FG002","numSubjects":"44"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Criteria from CSR","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"BG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"BG002","title":"Standard Therapy","description":"Standard Therapy"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"45"},{"groupId":"BG003","value":"128"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"72.5","spread":"8"},{"groupId":"BG001","value":"71.6","spread":"8.51"},{"groupId":"BG002","value":"68.8","spread":"9.36"},{"groupId":"BG003","value":"70","spread":"8.68"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"49"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"79"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Premature Discontinuation of Study or Study Drug Due to Any Reason","description":"The premature discontinuation of study or study drug due to any reason","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"28 week (randomisation visit to last follow up visit in study) according to protocols","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"}]}]}]},{"type":"PRIMARY","title":"Premature Discontinuation of Study Drug Due to Any Reason","description":"The premature discontinuation of study drug due to any reason","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"24 weeks (randomisation visit to last treatment visit)","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]}]},{"type":"PRIMARY","title":"Premature Discontinuation of Study Due to Any Reason","description":"\\|The premature discontinuation of study due to any reason","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"28 weeks (randomisation visit to last follow up visit)","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}]}]}]},{"type":"PRIMARY","title":"Compliance With Study Drug","description":"\\[(number of doses dispensed-number of doses returned)/number of days between visits\\]\\*100","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage","timeFrame":"24 weeks (randomisation visit to last treatment visit) according to protocol","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.95","spread":"16.503"},{"groupId":"OG001","value":"99.82","spread":"11.383"}]}]}]},{"type":"PRIMARY","title":"Compliance With Study Visits/Assessments","description":"(number of visits attended acroos the time of study divided by the number of expected visits according to the time of entry into study)\\*100","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage","timeFrame":"28 weeks (randomisation visit to last follow up visit) according to protocol","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","spread":"15.01"},{"groupId":"OG001","value":"95.6","spread":"10.45"},{"groupId":"OG002","value":"97.5","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Bleeding Events","description":"Number of patients with a bleeding event while on study drug. Patients with multiple bleeding events are counted once","populationDescription":"41 + 42 + 45 participants were randomized into the study to treatment arm 1, arm 2 and arm 3 respectively. However, one of the participants randomized to arm 2 was treated according to treatment arm 3","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was <24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"}]}]}]},{"type":"SECONDARY","title":"Change in Creatinine Level","description":"Individual change in Creatinine level (umil/L) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"umol/L","timeFrame":"4 weeks according to protocol (randomisation visit to week 4 visit)","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"8.64"},{"groupId":"OG001","value":"3.6","spread":"13.21"},{"groupId":"OG002","value":"2.6","spread":"12.90"}]}]}]},{"type":"SECONDARY","title":"Alanine Aminotransferase (ALAT)","description":"Number of patients while on study drug with Alanine aminotransferase (ALAT)\\>=3 times upper limit of normal.","populationDescription":"41 + 42 + 45 participants were randomized into the study to treatment arm 1, arm 2 and arm 3 respectively. However, one of the participants randomized to arm 2 was treated according to treatment arm 3","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was <24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}]},{"type":"SECONDARY","title":"Bilirubin","description":"Number of patients while on study drug with Bilirubin\\>=2 times upper limit of normal.","populationDescription":"41 + 42 + 45 participants were randomized into the study to treatment arm 1, arm 2 and arm 3 respectively. However, one of the participants randomized to arm 2 was treated according to treatment arm 3","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was <24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of AZD0837 (Prodrug)","description":"Assessment of plasma concentration of AZD0837 (prodrug) made on the week 4 visit","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"nmol/L","timeFrame":"4 weeks after baseline according to protocol","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"596.0","lowerLimit":"5.0","upperLimit":"2920.0"},{"groupId":"OG001","value":"636.0","lowerLimit":"18.2","upperLimit":"5920.0"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of AR-H067637XX (Active Metabolite)","description":"Assessment of plasma concentration of AR-H067637XX (active metabolite) made on the week 4 visit","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"nmol/L","timeFrame":"4 weeks after baseline according to protocol","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"258.5","lowerLimit":"5.0","upperLimit":"539.0"},{"groupId":"OG001","value":"368.5","lowerLimit":"159.0","upperLimit":"776.0"}]}]}]},{"type":"SECONDARY","title":"Change in D-Dimer Level","description":"Individual change in D-Dimer level (ng/ml) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"ng/ml","timeFrame":"4 weeks according to protocol.(baseline to week 4 visit)","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.484","lowerLimit":"-78.37","upperLimit":"288.13"},{"groupId":"OG001","value":"-41.445","lowerLimit":"-92.61","upperLimit":"130.00"},{"groupId":"OG002","value":"4.853","lowerLimit":"-80.12","upperLimit":"793.56"}]}]}]},{"type":"SECONDARY","title":"Activated Partial Thromboplastin Time (APTT)","description":"Individual change in Activated partial thromboplastin time (APTT) (sec) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"sec","timeFrame":"4 weeks according to protocol.(baseline to week 4 visit)","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.74","lowerLimit":"-17.8","upperLimit":"105.8"},{"groupId":"OG001","value":"51.51","lowerLimit":"3.1","upperLimit":"75.1"}]}]}]},{"type":"SECONDARY","title":"Ecarin Clotting Time (ECT)","description":"Individual change in Ecarin clotting time (ECT) (sec) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"sec","timeFrame":"4 weeks according to protocol.(baseline to week 4 visit)","groups":[{"id":"OG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg"},{"id":"OG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg"},{"id":"OG002","title":"Standard Therapy","description":"Standard Therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125.6","lowerLimit":"6","upperLimit":"274"},{"groupId":"OG001","value":"179.1","lowerLimit":"7","upperLimit":"341"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"41 + 42 + 45 participants were randomized into the study to treatment arm 1, arm 2 and arm 3 respectively. However, one of the participants randomized to arm 2 was treated according to treatment arm 3","eventGroups":[{"id":"EG000","title":"AZD0837 150 mg","description":"AZD0837 150 mg","seriousNumAffected":2,"seriousNumAtRisk":41,"otherNumAffected":3,"otherNumAtRisk":41},{"id":"EG001","title":"AZD0837 300 mg","description":"AZD0837 300 mg","seriousNumAffected":3,"seriousNumAtRisk":41,"otherNumAffected":1,"otherNumAtRisk":41},{"id":"EG002","title":"Standard Therapy","description":"Standard Therapy","seriousNumAffected":2,"seriousNumAtRisk":46,"otherNumAffected":1,"otherNumAtRisk":46}],"seriousEvents":[{"term":"Cardiac Failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":41},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":46}]},{"term":"Gastrointestinal Disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":41},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":1,"numAtRisk":46}]},{"term":"Drug Intolerance","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":41},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":46}]},{"term":"Podagra","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":41},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":1,"numAtRisk":46}]},{"term":"Renal Failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":41},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":46}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":41},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":46}]},{"term":"Deep Vein Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":41},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":46}]}],"otherEvents":[{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":41},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":1,"numAtRisk":46}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Gerard Lynch","organization":"AstraZeneca","email":"aztrial_results_posting@astrazeneca.com","phone":"+44 1509 645895"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M27273","name":"Systolic Murmurs","relevance":"LOW"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Knee","relevance":"HIGH"},{"id":"M17245","name":"Vitamin K","relevance":"LOW"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M16366","name":"Thrombin","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"},{"id":"T481","name":"Vitamin K","relevance":"LOW"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Vi","name":"Vitamins"}]}},"hasResults":true}